source
- Sofinnova Partners raises €725 million for second crossover fund targeting late-stage European biotech firmsSofinnova Partners announced the closing of its second crossover fund with €725 million ($815 million) in commitments. The fund is designed to fill the financing gap for late-stage European biopha…
- Industry groups push for clearer FDA guidance on ANDA and 505(b)(2) filings amid rising patent thicketsIndustry trade groups representing brand‑name and generic manufacturers have asked the FDA to clarify its recent guidance on when a company should file an abbreviated new drug application (ANDA) ve…